SCHEMBL3609386

SCHEMBL3609386

C=Cc1c(C)nn(C)c1Oc1cc(OCC(=O)O)c(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
CYP2C19 P33261 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
PTGDR Q13258 1/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 4/20 0.35
CYP2D6 P10635 1/20 0.34
MAPK1 P28482 1/20 0.34
PKM P14618 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609830 0.86 NR2F2 (0.37) SMN1; SMN2CYP2C19CYP1A2CYP2C9TSHR
SCHEMBL3607366 0.83 SMN1; SMN2 (0.35) SMN1; SMN2CYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL3617492 0.83 L3MBTL1 (0.39) SMN1; SMN2CYP2C19TDP1CYP1A2CYP2C9
SCHEMBL3602126 0.83 KMT2A (0.38) SMN1; SMN2TSHRALDH1A1HTTHPGD
SCHEMBL3612119 0.82 SMN1; SMN2 (0.36) SMN1; SMN2CYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL3609770 0.82 SMN1; SMN2 (0.37) SMN1; SMN2CYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL3608916 0.82 KDM4E (0.39) SMN1; SMN2CYP2C19CYP1A2CYP2C9TSHR
SCHEMBL3603940 0.82 KDM4E (0.39) SMN1; SMN2CYP2C19CYP1A2CYP2C9TSHR
SCHEMBL3605072 0.82 KDM4E (0.39) SMN1; SMN2CYP2C19CYP1A2CYP2C9TSHR
SCHEMBL3606802 0.81 PTGDR2 (0.35) SMN1; SMN2CYP2C19CYP1A2CYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R SMN1; SMN2 4515/4885CYP2C19 79/4885TDP1 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.